Autopsy report · NCT03061305

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

“Sponsor's discretion to termination due to business decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 7 years 7 months before it stopped.
• 58,213 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Strata Oncology

Sponsor type

Industry

Conditions

Cancer; Adult Solid Tumor; Lymphoma; Multiple Myeloma

Participants

58,213

Sites

40

Countries

United States

Trials that died the same way

• Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft
  “Sponsor termination” (88% match in meaning)
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (87% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (87% match in meaning)
• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (86% match in meaning)
• A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
  “The sponsor voluntarily requested termination” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.